You are here

FDA's MedWatch Updates

Viramune (nevirapine) - FDA issued a public health advisory to inform health care providers and patients about recent safety-related changes to the nevirapine (Viramune) label and about appropriate use of HIV triple combination therapy containing nevirapine.
(Posted 01/19/2005)

Methylin CT (Methylphenidate HCl Chewable Tablets) - Recall of one lot due to health risk associated with excess active ingredient in product.
(Posted 01/19/2005)

Aranesp (darbepoetin alfa) - WARNINGS and PRECAUTIONS sections revised to include reports of increased mortality and thrombotic vascular events.
(Posted 01/14/2005)

Source: MedWatch, the FDA Safety Information and Adverse Event Reporting Program

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks